A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia

European Urology

Volumn 48, Issue 3, 2005, Pages 445-452

  Roehrborn, Claus G ^a   Prajsner, Andrzej ^b   Kirby, Roger ^c   Andersen, Morton ^d   Quinn, Sheila ^e   Mallen, Sharon ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d Moelv Spesialistsenter ^*  (Norway)

^e PFIZER INC   (United States)

Author keywords

Benign prostatic hyperplasia; Doxazosin; GITS; Lower urinary tract symptoms

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SCORING SYSTEM; SOMNOLENCE; SYMPTOM; URINE FLOW RATE; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DOXAZOSIN; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 23944455849     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.05.010     Document Type: Article

References (21)

1. C.R. Chapple Medical therapy and quality of life Eur Urol 34 1998 10 17
2. T. Tammela Benign prostatic hyperplasia. Practical treatment guidelines Drugs Aging 10 1997 349 366
3. P. Boyle, G.F. Liu, S. Jacobsen, O. Ogawa, K. Oishi, and P. O'Reilly Benign prostatic hyperplasia C. Chatelain L.J. Denis K.T. Foo S. Khoury J.S. McConnell 5th International Consultation on Benign Prostatic Hyperplasia (BPH) Plymouth: Health Publication Ltd. 2000 17 68
4. S.J. Berry, D.S. Coffey, P.C. Walsh, and L.L. Ewing The development of human benign prostatic hyperplasia with age J Urol 132 1984 474 479
5. C.G. Roehrborn, and D.A. Schwinn Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia J Urol 171 2004 1029 1035
6. R. Kirby, K.E. Andersson, H. Lepor, and W.D. Steers Alpha(1)-adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms Prostate Cancer Prostatic Dis 3 2000 76 83
7. B. Fulton, A. Wagstaff, and E. Sorkin Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia Drugs 49 1995 295 320
8. M. Chung, V. Vashi, J. Puente, M. Sweeney, and P. Meredith Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation Br J Clin Pharmacol 48 1999 678 687
9. M. Andersen, C. Dahlstrand, and K. Hoye Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia Eur Urol 38 2000 400 409
10. P. Gratzke, and R. Kirby Doxazosin GITS und herkommliches Doxazosin zur Behandlung der benignen Prostatahyperplasie. Doppelblindstudie zur Wirksamkeit und Vertraglichkeit MMW Fortschr Med 118 Suppl 2 2000 83 92
11. R.S. Kirby, M. Andersen, P. Gratzke, C. Dahlstrand, and K. Hoye A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia BJU Int 87 2001 192 200
12. R.S. Kirby A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia BJU Int 91 2003 41 44
13. R.S. Kirby, S. Quinn, S. Mallen, and D. Jensen Doxazosin controlled release vs. tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis Int J Clin Pract 58 2004 6 10
14. A. Fawzy, A. Hendry, E. Cook, and F. Gonzalez Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension Int J Urol 6 1999 346 354
15. J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole Jr., C.M. Dixon, and J.W. Kusek The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
16. L.S. Marks, C.G. Roehrborn, M. Gittelman, D. Kim, J. Forrest, and S. Jacobs First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia Urology 62 2003 888 893
17. S.P. Curtis, I. Eardley, M. Boyce, P. Larson, R. Haesen, and K. Gottesdiener Single dose methodology to assess the influence of an alpha1- adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia Br J Clin Pharmacol 49 2000 269 273
18. H. Lepor Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group Urology 51 1998 892 900
19. P. Narayan, and A. Tewari A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group J Urol 160 1998 1701 1706
20. I. Os, and H.P. Stokke Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group J Cardiovasc Pharmacol 33 1999 791 797
21. P. Narayan, M.P. O'Leary, and G. Davidai Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial J Appl Res 5 2005 237 245